Total Payments
$6,013
2024 Payments
$1,033
Companies
36
Transactions
325
Medicare Patients
14,259
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$5,875 (97.7%)
Education$137.95 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,875 | 319 | 97.7% |
| Education | $137.95 | 6 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,475 | 89 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $773.16 | 45 | $0 (2023) |
| PFIZER INC. | $720.88 | 44 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $334.94 | 11 | $0 (2024) |
| Amgen Inc. | $282.24 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $255.92 | 11 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $217.97 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $214.68 | 12 | $0 (2024) |
| Bardy Diagnostics, Inc. | $200.00 | 8 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $197.84 | 9 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,033 | 53 | Novartis Pharmaceuticals Corporation ($403.27) |
| 2023 | $1,031 | 59 | Novartis Pharmaceuticals Corporation ($448.52) |
| 2022 | $679.42 | 35 | Novartis Pharmaceuticals Corporation ($150.80) |
| 2021 | $509.53 | 28 | Novartis Pharmaceuticals Corporation ($222.75) |
| 2020 | $636.71 | 24 | Biosense Webster, Inc. ($119.04) |
| 2019 | $644.00 | 31 | Janssen Pharmaceuticals, Inc ($169.14) |
| 2018 | $785.13 | 46 | Janssen Pharmaceuticals, Inc ($126.61) |
| 2017 | $693.63 | 49 | Gilead Sciences Inc ($141.43) |
All Payment Transactions
325 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $31.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $16.18 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: DIABETES | ||||||
| 10/28/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $30.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Obesity | ||||||
| 10/10/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.11 | General |
| 10/09/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $29.36 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/30/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $22.96 | General |
| Category: Cardiology | ||||||
| 09/25/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $39.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.03 | General |
| Category: Cardiovascular | ||||||
| 08/09/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/08/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/06/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Not Applicable | ||||||
| 08/05/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.64 | General |
| 07/29/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.52 | General |
| Category: Cardiovascular | ||||||
| 07/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/27/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 3,642 | 5,722 | $2.7M | $803,216 |
| 2022 | 21 | 3,795 | 5,986 | $2.7M | $756,295 |
| 2021 | 22 | 3,789 | 5,776 | $2.0M | $763,529 |
| 2020 | 21 | 3,033 | 4,482 | $1.2M | $438,104 |
Total Patients
14,259
Total Services
21,966
Medicare Billing
$2.8M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 249 | 250 | $874,500 | $269,884 | 30.9% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 249 | 490 | $598,780 | $196,777 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 555 | 908 | $284,930 | $80,119 | 28.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 299 | 1,161 | $177,725 | $51,088 | 28.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 306 | 315 | $151,423 | $40,340 | 26.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 127 | 306 | $89,332 | $27,851 | 31.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 84 | 84 | $90,205 | $27,434 | 30.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 37 | 38 | $77,710 | $24,325 | 31.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 360 | 363 | $63,130 | $18,319 | 29.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 131 | 131 | $53,421 | $14,005 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 146 | 163 | $36,171 | $10,049 | 27.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 639 | 878 | $31,544 | $8,955 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 68 | $29,966 | $8,683 | 29.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 62 | 63 | $26,931 | $8,302 | 30.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 83 | $16,185 | $5,070 | 31.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 90 | 90 | $15,106 | $4,641 | 30.7% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 82 | 160 | $45,760 | $2,906 | 6.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,642 | $1,694 | 30.0% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 50 | 53 | $3,339 | $996.54 | 29.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 13 | 13 | $2,886 | $878.22 | 30.4% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 20 | 71 | $2,059 | $592.28 | 28.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 11 | 11 | $571.00 | $179.08 | 31.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 12 | 12 | $419.00 | $129.12 | 30.8% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2022 | 198 | 198 | $637,744 | $216,179 | 33.9% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2022 | 198 | 396 | $740,608 | $160,095 | 21.6% |
About Dr. Kent Chen, MD
Dr. Kent Chen, MD is a Cardiovascular Disease healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174623144.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kent Chen, MD has received a total of $6,013 in payments from pharmaceutical and medical device companies, with $1,033 received in 2024. These payments were reported across 325 transactions from 36 companies. The most common payment nature is "Food and Beverage" ($5,875).
As a Medicare-enrolled provider, Chen has provided services to 14,259 Medicare beneficiaries, totaling 21,966 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Phoenix, AZ
- Active Since 09/22/2006
- Last Updated 06/29/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1174623144
Products in Payments
- ENTRESTO (Drug) $795.60
- XARELTO (Drug) $773.16
- ELIQUIS (Drug) $733.10
- LEQVIO (Drug) $679.27
- LifeVest (Device) $334.94
- Repatha (Biological) $264.29
- Carnation Ambulatory Monitor (Device) $200.00
- BRILINTA (Drug) $176.27
- VYNDAQEL (Drug) $148.68
- PRALUENT (Drug) $139.85
- Carto 3 System (Device) $119.04
- JARDIANCE (Drug) $114.85
- PRADAXA (Drug) $103.12
- BYSTOLIC (Drug) $99.65
- Vascepa (Drug) $87.37
- INJECTAFER (Drug) $76.48
- FARXIGA (Drug) $59.84
- PRALUENT ALIROCUMAB INJECTION (Biological) $58.46
- MULTAQ (Drug) $57.99
- Arcalyst (Drug) $54.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Phoenix
Ashish Gupta, M.d, M.D
Cardiovascular Disease — Payments: $1.2M
Cardiovascular Disease $1.2M
Dr. Timothy Byrne, Do, DO
Cardiovascular Disease — Payments: $838,695
Cardiovascular Disease $838,695
Dr. J. Weiss, M.d, M.D
Cardiovascular Disease — Payments: $288,755
Cardiovascular Disease $288,755
Tabitha Moe, M.d, M.D
Cardiovascular Disease — Payments: $154,170
Cardiovascular Disease $154,170
Dr. Akil Loli, Md, MD
Cardiovascular Disease — Payments: $139,062
Cardiovascular Disease $139,062
Mark Seifert, Md, MD
Cardiovascular Disease — Payments: $132,833
Cardiovascular Disease $132,833